newsfilter
← Latest News
Business Wire·

Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis

—Company now anticipates MOMENTUM topline data readout by the end of January 2022— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has sho